Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 23, Issue 2, Pages 1343-1353Publisher
WILEY
DOI: 10.1111/jcmm.14037
Keywords
CD19; IL-10; miR-15a/16; Tim-1; tumor
Categories
Funding
- National Natural Science Foundation of China [81273214, 81471547, 81671547, 81873867]
- Innovation Project for Graduate Students in Jiangsu Province [SJZZ16_0267]
- Natural Science Foundation of Jiangsu Province [BK 20180925]
Ask authors/readers for more resources
IL-10-producing B cells (B10) are associated with autoimmune diseases, infection and tumours. MiR-15a/16 as a tumour-suppressive gene is down-regulated in several tumours, such as chronic lymphocytic leukaemia, pituitary adenomas and prostate carcinoma. Here, increased frequency of IL-10-producing CD19(+) Tim-1(+) cells was seen in both aged miR-15a/16(-/-) mice (15-18 months) with the onset of B cell leukaemia and young knockout mice (8-12 weeks) transplanted with hepatic cancer cells. CD19(+) Tim-1(+) cells down-regulated the function of effector CD4(+) CD25(low) T cells ex vivo dependent on IL-10 production, and adoptive transfer of CD19(+) Tim-1(+) cells promoted tumour growth in mice. IL-10 production by CD19(+) Tim-1(+) cells was involved with the STAT3 activation. Bioinformatics analysis shows that miR-16 targets the 3'-untranslating region (3'-UTR) of STAT3 mRNA. Overexpression of miR-16 in CD19(+) Tim-1(+) cells inhibited STAT3 transcription and its protein expression. Thus, the loss of miR-15a/16 promoted induction of regulatory CD19(+) Tim-1(+) cells in tumour microenvironment. These results confirmed that miR-15a/16 could be used in tumour therapy due to its inhibition of tumour and regulatory B cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available